RegenLife Centers · Physician-led care
Chronic Fatigue Syndrome
What Functional Medicine Reveals That Standard Care Misses
Published on November 19th, 2026


The 43-year-old woman who has spent three years explaining to physicians that her fatigue is not like being tired, who has had her TSH checked and found "within normal limits," her CBC reviewed and found unremarkable, her metabolic panel evaluated and returned without flags, who was told at one appointment that her symptoms were likely stress-related and at another that she should try exercising more, a recommendation that caused her to spend the following two days unable to leave her bed not from lack of willpower but from a physiological response her body imposed on the exertion with the consistency of a biological law, who has watched her career narrow, her social commitments shrink to what she can complete without triggering the post-exertional collapse that arrives six to forty-eight hours after activity like a debt she did not choose to incur, who has never been told that the CDC estimates more than 9 in 10 people with her condition have never received a formal diagnosis, that the National Academies of Medicine places the undiagnosed fraction between 84% and 91%, and that the "normal" panels her physicians reviewed were designed for population screening rather than for detecting the mitochondrial architecture damage, HPA axis dysregulation, natural killer cell exhaustion, and gut-brain axis disruption that functional medicine evaluation identifies in patients whose standard bloodwork looks entirely unremarkable: this patient has not been told there is another approach.
Chronic fatigue syndrome, formally designated myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is a complex, multi-system condition involving measurable biological dysfunction across immune, endocrine, neurological, and gastrointestinal systems, and chronic fatigue syndrome is not a diagnosis of exclusion that emerges when everything else has been ruled out; it is a condition with its own biological substrate that functional medicine evaluation is specifically designed to characterize. At RegenLife Centers for Integrative Pain & Weight Management, the approach to chronic fatigue syndrome begins not with symptom management but with the comprehensive diagnostic picture, hormonal, immunological, mitochondrial, and microbiome, that determines why a specific patient's body is operating in a state of biological energy deficit, and what targeted interventions address the root causes driving that deficit.
Woman with hand on forehead, showing fatigue and exhaustion in a clinical contextKey Takeaways
- The CDC estimates more than 9 in 10 people with ME/CFS have never received a diagnosis, and the condition affects an estimated 3.35 million American adults: a prevalence that has grown significantly in the post-COVID era, where 73.5% of long COVID clinic patients present with ME/CFS-defining fatigue
- Functional medicine evaluation identifies measurable biological dysfunction standard panels do not assess: mitochondrial architecture damage, HPA axis hypofunction, natural killer cell cytotoxicity reduced to roughly half of normal capacity, gut microbiome dysbiosis, intestinal permeability, and autoantibodies that standard workups do not include
- Up to 92% of ME/CFS patients experience comorbid IBS, and gut dysbiosis: specifically reductions in butyrate-producing bacteria and increases in pro-inflammatory gram-negative bacteria, is a mechanistically significant driver of the neuroinflammation producing cognitive symptoms, not merely a coincidental finding
- Graded exercise therapy, once the standard recommendation for ME/CFS, is now contradicted by research showing it causes tangible harm through exercise-induced inflammation and amyloid accumulation in muscle tissue: the functional medicine approach substitutes targeted energy management, mitochondrial support, and carefully paced movement for the exertion-escalation model that standard care applied for decades
Understanding Chronic Fatigue Syndrome: What ME/CFS Actually Is
The Diagnostic Criteria Standard Care Often Applies Incompletely
The 2015 Institute of Medicine (now the National Academy of Medicine) diagnostic criteria for ME/CFS require three core features: substantially impaired ability to engage in pre-illness activities, unrefreshing sleep, and post-exertional malaise (PEM), the hallmark worsening of symptoms following physical or cognitive exertion that can be delayed by 12 to 48 hours. These criteria also require at least one of two additional features: cognitive impairment or orthostatic intolerance. Fatigue must persist for six months or longer.
The diagnostic problem is not that the criteria are ambiguous. It is that PEM, the most diagnostically specific feature of ME/CFS, is routinely undertreated as a complaint rather than investigated as a physiological signal. A patient who reports that a 20-minute walk leaves her non-functional for two days is describing a measurable biological abnormality, the failure of cellular energy production to recover from aerobic demand, not a motivational deficit. Standard medicine's response to PEM is frequently "try to push through" or "start slow and build up," recommendations that direct evidence now shows cause harm in this population precisely because the cellular mechanism driving PEM is not deconditioning but energy metabolism failure.
Why So Many Patients Go Undiagnosed for Years
The published reasons for diagnostic delay in ME/CFS are consistent across studies: insufficient knowledge at the primary care level, the requirement for comprehensive differential diagnosis that time-constrained appointments cannot accommodate, and, historically, negative attitudes toward the condition's biological legitimacy that led generations of clinicians to misattribute ME/CFS presentations to depression, somatization, or inadequate effort. An estimated 3.35 million American adults currently live with ME/CFS, and the population of undiagnosed patients is at minimum three to four times larger than the diagnosed population. In pediatric populations, up to 95% of children meeting diagnostic criteria have never received the diagnosis.
The practical consequence is that most patients with ME/CFS reach a functional medicine evaluation only after years of inconclusive standard workups, multiple psychiatric referrals, and a succession of normal labs that confirmed nothing was wrong with them while everything was wrong with them, a situation the biological research of the past three years has systematically addressed by identifying specific, measurable, reproducible abnormalities across multiple biological systems.
The Biology of ME/CFS: What Functional Medicine Sees That Standard Panels Miss
Lab technician operating a centrifuge for blood analysis in a medical laboratoryMitochondrial Dysfunction at the Cellular Level
The biological mechanism most consistently implicated in ME/CFS's defining symptom, the inability to sustain physical or cognitive activity without disproportionate, prolonged recovery, is mitochondrial dysfunction: specifically, the failure of cells to generate and regenerate ATP at rates that normal activity demands. A landmark 2023 study published in PNAS by NIH researchers identified WASF3 protein overproduction, triggered by endoplasmic reticulum stress, as a mechanism that directly disrupts the assembly of mitochondrial respiratory supercomplexes, preventing efficient ATP conversion. When researchers engineered mice to overexpress WASF3, the mice demonstrated immediate, marked reductions in exercise capacity, a direct animal model of the exercise intolerance that ME/CFS patients experience.
A 2024 study using electron microscopy deepened this finding: ME/CFS patients showed severely degraded mitochondrial cristae, the internal membrane structures where the electron transport chain operates, with simultaneous necrosis and regeneration indicating ongoing, repeated mitochondrial injury. Standard blood panels do not assess mitochondrial function. Functional medicine evaluation includes the organic acid testing, CoQ10 levels, and mitochondrial marker panels that characterize cellular energy production rather than inferring it from serum chemistry.
HPA Axis Hypofunction and Cortisol Dysregulation
The hypothalamic-pituitary-adrenal (HPA) axis, the neuroendocrine cascade that governs the body's stress response, energy mobilization, and immune regulation, is consistently dysregulated in ME/CFS, but in a direction that standard stress paradigms do not anticipate. Rather than the elevated cortisol of acute stress response, ME/CFS patients demonstrate mild hypocortisolism: reduced basal cortisol, a flattened cortisol awakening response (CAR), attenuated response to HPA stimulation, and enhanced negative feedback that suppresses cortisol production. This is not adrenal insufficiency in the classical sense. It is a subtler dysregulation of the entire axis that produces fatigue, cognitive impairment, immune suppression, and orthostatic intolerance through mechanisms that a single morning cortisol draw will not detect.
The DUTCH Complete, a dried urine assessment of cortisol, DHEA-S, cortisol metabolites, and the cortisol awakening response measured across multiple collection points, provides the HPA axis characterization that a spot serum cortisol cannot. The hormone testing available through RegenLife's diagnostic services specifically includes the adrenocortical stress profile and CAR assessment that characterize this dysregulation pattern before any treatment is selected.
Immune Exhaustion and the Natural Killer Cell Deficit
A 2024 meta-analysis confirmed that natural killer (NK) cell cytotoxicity is significantly reduced in ME/CFS patients, operating at roughly half the functional capacity of healthy controls. NK cells are the immune system's front-line surveillance cells, responsible for identifying and eliminating virus-infected cells and tumor cells without requiring prior sensitization. In ME/CFS, genetic variations including KIR3DL3*002 send inhibitory signals that suppress NK cell activation, leaving the immune system in a state of functional exhaustion that cannot mount adequate responses to viral reactivation, which is why Epstein-Barr virus, human herpesvirus 6, and other latent viral infections frequently reactivate in ME/CFS patients and sustain the inflammatory burden that drives symptoms.
A UK Biobank study comparing 1,455 ME/CFS patients to controls identified significant differences in both 290 distinct blood markers spanning immune activation, metabolic dysregulation, and vascular inflammation, findings that no single standard panel captures and that comprehensive functional evaluation begins to characterize by mapping immune activation markers, inflammatory cytokines, and pathogen-specific antibody patterns against the patient's clinical presentation.
Gut Dysbiosis and Neuroinflammation: Overlooked Drivers of ME/CFS Symptoms
The Gut-Brain Axis in Myalgic Encephalomyelitis
Up to 92% of ME/CFS patients experience comorbid irritable bowel syndrome, a co-occurrence rate that is not coincidental and is not explained by stress alone. The gut microbiome in ME/CFS patients shows consistent, measurable compositional disruption: decreased butyrate-producing bacteria, particularly Faecalibacterium prausnitzii, now considered a potential biomarker for the condition, reduced overall bacterial diversity, and increased pro-inflammatory gram-negative bacteria including Alistipes, Bacteroidetes, and Enterobacteriaceae species.
Butyrate is the short-chain fatty acid that intestinal epithelial cells depend on as their primary energy source; it also regulates intestinal barrier integrity and suppresses inflammatory signaling. When butyrate-producing populations are reduced, the intestinal epithelium loses the fuel and signaling that maintain barrier function, leading to increased intestinal permeability, the translocation of microbial products including lipopolysaccharide (LPS) into systemic circulation, and the downstream activation of the neuroinflammatory cascade that drives the cognitive impairment ME/CFS patients describe as "brain fog." This is the mechanistic pathway the gut-brain axis research has traced: from microbial community disruption, through compromised barrier function, to systemic endotoxemia, to neuroinflammation, a cascade that begins in the gut and manifests in the brain.
Intestinal Permeability and the Systemic Inflammatory Cascade
The GI-MAP stool test, which measures zonulin (a direct marker of intestinal permeability), pathogenic bacterial and parasitic load, commensal bacterial populations, and inflammatory markers, provides the specific microbiome characterization that standard stool cultures were not designed to deliver. Zonulin levels correlate with the degree of barrier disruption; research has documented symptom improvement in ME/CFS patients when intestinal permeability is addressed through targeted probiotic and prebiotic intervention.
Clinical intervention data from probiotic studies in ME/CFS is encouraging: a VSL#3 eight-strain consortium produced significant fatigue reduction on validated scales within four weeks, and a synbiotic formula with inulin demonstrated a two-fold fatigue reduction versus placebo. A two-week ImmunoSEB plus enzyme protocol resulted in 87% of treated patients becoming fatigue-free in the reported study cohort, outcomes consistent with the mechanistic model of gut-driven neuroinflammation being a primary, addressable driver of ME/CFS symptom burden. These are not outcomes from treatments that suppress symptoms; they are outcomes from interventions that address the specific biological disruption driving them.
Functional Medicine Testing for Chronic Fatigue Syndrome
Healthcare professional reviewing patient medical history and laboratory results in a consultation settingThe Diagnostic Panel Standard Care Rarely Orders
The functional medicine evaluation for ME/CFS is not a longer version of the standard panel. It is a fundamentally different set of questions addressed to different biological systems. Where standard care orders a CBC, CMP, and TSH and reads results against population reference ranges, functional evaluation characterizes the specific subsystems, adrenal, mitochondrial, immune, gastrointestinal, and infectious, that research has identified as mechanistically implicated in ME/CFS.
The specific assessments that constitute a comprehensive ME/CFS evaluation at RegenLife include:
- Infectious panel: evaluating immune activation against Epstein-Barr virus, human herpesvirus 6, hepatitis C, and Lyme disease, because latent viral reactivation sustains the immune exhaustion and inflammatory burden that perpetuates ME/CFS in a significant subset of patients
- DUTCH Complete: dried urine assessment of cortisol pattern across the day, cortisol awakening response, DHEA-S, sex hormones, and organic acids reflecting neurotransmitter and nutrient status
- hs-CRP and inflammatory cytokines: characterizing the systemic inflammatory burden that correlates with symptom severity and responds to targeted intervention
- GI-MAP stool analysis: zonulin, microbial composition, intestinal permeability markers, and pathogen load
- Heavy metals (24-hour urine): evaluating lead, mercury, arsenic, and cadmium, which independently impair mitochondrial function, immune activity, and neurological health
- Organic acid testing: providing direct markers of mitochondrial function, oxidative stress, and neurotransmitter metabolism that serum chemistry does not capture
What Comprehensive Hormone and Adrenal Assessment Reveals
The adrenocortical profile that emerges from comprehensive testing in ME/CFS frequently shows the pattern of HPA axis hypofunction described above: flattened morning cortisol, absent or blunted cortisol awakening response, and DHEA-S levels that have declined below the range appropriate for the patient's age, a pattern that explains the unrefreshing sleep, morning dysfunction, and vulnerability to post-exertional crashes that patients describe and that a single cortisol draw does not capture. The adrenal fatigue pattern that many patients suspect when they describe their symptoms is mechanistically real, but it is an HPA axis dysregulation, not a primary adrenal gland failure, and its treatment requires the comprehensive hormonal context that functional evaluation provides.
Thyroid function also requires full characterization in ME/CFS patients: not TSH alone, but free T3, free T4, reverse T3, and thyroid antibodies. Low-normal TSH with reduced free T3, a pattern of impaired T4-to-T3 conversion driven by the chronic inflammation and cortisol dysregulation ME/CFS produces, creates a cellular hypothyroid state that explains fatigue, cognitive slowing, and cold intolerance in patients whose TSH is "within normal limits."
Post-COVID and ME/CFS: Why Long Haulers Represent a Growing Patient Population
The Overlap Between Long COVID and Myalgic Encephalomyelitis
The post-COVID pandemic has produced a dramatic increase in the population presenting with ME/CFS-defining symptoms. 73.5% of patients presenting to long COVID referral clinics present with fatigue meeting ME/CFS diagnostic criteria, a convergence that reflects not coincidence but shared pathophysiology: post-infectious immune dysregulation, HPA axis disruption, gut microbiome alteration, and mitochondrial dysfunction triggered by viral injury rather than pre-existing susceptibility. Dr. Anthony Fauci described long COVID presentations as "strikingly similar to myalgic encephalomyelitis/chronic fatigue syndrome", a clinical observation that the biological research has since confirmed mechanistically.
The gut microbiome data is particularly convergent: long COVID patients demonstrate the same patterns of butyrate-producing bacteria depletion and intestinal permeability increase seen in ME/CFS, and approximately 87% of acute COVID-19 patients report ME/CFS-like symptoms during recovery. The distinction between "long COVID fatigue" and "post-infectious ME/CFS" is increasingly semantic, the biological substrate and the functional medicine evaluation required to characterize it are the same. The post-COVID chronic pain and fatigue evaluation at RegenLife treats both presentations through the same root-cause framework.
Why the Post-Infectious Mechanism Matters for Treatment
Understanding that ME/CFS frequently follows an infectious trigger, Epstein-Barr virus in adolescents and young adults, enteroviruses, COVID-19, and other viral illnesses that dysregulate the immune system and alter the gut microbiome, has direct treatment implications. The patient whose ME/CFS follows identifiable viral onset and who tests positive for persistent EBV reactivation or elevated HHV-6 antibody titers has a specific biological target, viral-driven immune dysregulation, that antiviral support, immune modulatory interventions, and targeted nutritional protocols address differently than the patient whose presentation is primarily driven by HPA axis hypofunction or heavy metal burden. This is why the infectious panel is a component of ME/CFS evaluation rather than an afterthought: the post-infectious subset has a different primary driver and a different treatment priority.
The Functional Medicine Treatment Approach: Root Causes Rather Than Symptom Management
An assortment of supplement capsules and vitamins representing targeted nutritional support for mitochondrial functionNutritional and Mitochondrial Support
The nutritional interventions with the strongest mechanistic rationale in ME/CFS address the specific cellular deficits the functional evaluation identifies. Coenzyme Q10 (CoQ10), the electron carrier essential for mitochondrial respiratory chain function, is depleted in ME/CFS patients and has shown symptom improvement in clinical studies when supplemented at therapeutic doses. D-ribose, the five-carbon sugar that serves as the backbone for ATP synthesis, addresses the energy substrate deficit that mitochondrial dysfunction creates. Magnesium is required as a cofactor for more than 300 enzyme reactions including those governing ATP synthesis and muscle function; deficiency, common in ME/CFS and frequently undetected by serum magnesium, which does not reflect intracellular stores, produces the muscle pain, sleep disruption, and cognitive symptoms that patients prioritize most.
The case for intravenous delivery of these nutrients, bypassing the gastrointestinal absorption barriers that limit oral bioavailability, is developed at length in the IV nutrient therapy approach at RegenLife. For ME/CFS patients with comorbid gut dysfunction, the absorption barriers to oral supplementation are not hypothetical; they are the same intestinal permeability and dysbiosis that is driving a portion of their symptoms. IV magnesium, B12, B complex, and vitamin C deliver the nutrients that the compromised gut cannot adequately absorb from oral formulations. Similarly, NAD+ therapy addresses the cellular energy production deficit at the coenzyme level that underlies the fatigue and cognitive symptoms ME/CFS generates.
Adaptogenic herbs, specifically ashwagandha and Rhodiola rosea, both with clinical evidence for HPA axis support, address the cortisol dysregulation pattern by modulating the stress response rather than suppressing or forcing it. These are not interchangeable; the specific adaptogen, dose, and timing are calibrated to the individual's cortisol pattern as the DUTCH assessment characterizes it.
Gut Restoration and Microbiome Optimization
The gut intervention in ME/CFS is not generic probiotic supplementation. It is targeted restoration of the specific populations whose absence is driving the inflammatory cascade. High-dose Lactobacillus and Bifidobacterium species, including Bifidobacterium infantis 35624, which reduced CRP and IL-6 in 70% of ME/CFS patients in a published trial, address the immune dysregulation that dysbiosis maintains. Butyrate precursors, fermentable prebiotic fibers including inulin and resistant starch, feed the Faecalibacterium and Roseburia populations whose restoration reduces intestinal permeability and reverses the LPS-driven neuroinflammatory cascade.
The dietary framework that supports microbiome restoration in ME/CFS emphasizes diversity, the single strongest predictor of microbial community health, through varied plant fiber intake, fermented foods (yogurt, kefir, sauerkraut, kimchi), and elimination of the ultra-processed, high-glycemic foods that selectively feed pro-inflammatory bacterial populations. Elimination diet protocols that identify the food sensitivities that increased intestinal permeability has generated are also part of the gut restoration phase: the ME/CFS patient with leaky gut frequently develops immune reactivity to food proteins that her intact gut would have tolerated, and removing these immune-activating foods reduces the inflammatory burden while the barrier is being restored.
Pacing, Lifestyle, and the Case Against Graded Exercise Therapy
Graded exercise therapy (GET), once the standard recommendation for ME/CFS, is now directly contradicted by the biological evidence. 2024 research demonstrated that post-exertional malaise in ME/CFS causes severe damage and macrophage infiltration in skeletal muscle, along with amyloid-containing deposits typically associated with neurodegenerative disease, findings that explain why increasing exercise load in ME/CFS patients causes harm rather than adaptation. The energy envelope model, where the patient stays within her available energy capacity rather than pushing through its limits, is the evidence-based substitute, supported by pacing strategies, heart rate monitoring to stay below anaerobic threshold, and cognitive load management alongside physical activity management.
The lifestyle medicine protocols at RegenLife integrate sleep optimization, stress management, and gentle movement, walking, swimming, low-impact yoga within the individual's energy envelope, with the biological interventions. Sleep is not merely a comfort measure in ME/CFS; it is the period during which HPA axis recalibration, immune restoration, and mitochondrial repair occur, and unrefreshing sleep in ME/CFS reflects measurable disruption of these restorative processes rather than simple insomnia. Sleep architecture optimization, including melatonin supplementation calibrated to the DUTCH assessment's melatonin output, blue light management, and the removal of the stimulants and cortisol-activating exposures that compound HPA dysregulation, is a clinical intervention, not a lifestyle suggestion.
The Integrated Evaluation at RegenLife: Chronic Fatigue Syndrome in Cincinnati
The evaluation of chronic fatigue syndrome at RegenLife begins with the premise that a patient who has had normal standard labs is not a patient who has had a complete evaluation, she is a patient who has had an evaluation designed to screen for disease states that are different from hers. The diagnostic services characterization at RegenLife encompasses the HPA axis assessment, mitochondrial markers, gut microbiome analysis, infectious panel, and inflammatory markers that together distinguish between the presentations that look similar symptomatically but have different primary drivers and different treatment priorities.
The patient whose fatigue is primarily driven by HPA axis hypofunction following years of chronic stress is a different biological presentation than the patient whose fatigue follows Epstein-Barr virus reactivation, whose gut dysbiosis is generating the neuroinflammation, and whose mitochondrial architecture was disrupted by the same viral event, and treating them identically, with the same supplements and the same lifestyle advice, produces the inconsistent results that make ME/CFS treatment appear to be guesswork when it is practiced without the diagnostic framework that functional evaluation provides.
The hormone therapy at RegenLife addresses the testosterone, estrogen, and thyroid dysregulation that independently impairs the cellular uptake and utilization of the nutrients that IV therapy and supplementation deliver. The patient with undertreated testosterone deficiency, female or male, is delivering mitochondrial support into a hormonal environment that reduces the anabolic response those nutrients are designed to support; the patient with unrecognized subclinical hypothyroidism has an energy production deficit at the thyroid hormone level that no amount of CoQ10 or B12 corrects. The regenerative medicine for fibromyalgia overlap with ME/CFS, both conditions involve mitochondrial dysfunction, neuroinflammation, and HPA axis dysregulation, means that patients with overlapping presentations benefit from the same comprehensive evaluation framework.
Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.
Frequently Asked Questions
Find answers to common questions
Ready to Learn More?
To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.
About the Author

Caitlyn Benton, Research Manager at RegenLife
As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.
Reviewed and Approved by

Dr. Zeeshan Tayeb, Medical Director at RegenLife
Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.
Disclaimer:
As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Stay Updated With Our Latest News
Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.
Get In Touch
Same-week consults. Real follow-through.
Tell us what's going on. A coordinator will follow up during office hours to help book your visit.
Choose the clinic that works for you.
Most new patients can be seen within the same week.
We accept most major insurance plans